ICD-10 · PDGM grouping
C48 Malignant neoplasm of retroperitoneum and peritoneum
All 4 codes in the C48 family, with the PDGM clinical group, comorbidity subgroup and primary-position rule CMS assigns, read from the CMS grouper crosswalk v07.2.26 and the CDC FY2027 code file.
Codes in family
4
Can lead a claim
4
Cannot lead a claim
0
What CMS assigns to C48
All 4 codes group to MMTA - Infectious Disease, Neoplasms, and Blood-Forming Diseases. All 4 count toward the Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum comorbidity subgroup. Every code can lead a claim.
- Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum
Every code in C48
Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.
| Code | Description | Primary position | Clinical group | Comorbidity subgroup |
|---|---|---|---|---|
| C48.0 | Malignant neoplasm of retroperitoneum | Can lead a claim | K | Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum |
| C48.1 | Malignant neoplasm of specified parts of peritoneum | Can lead a claim | K | Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum |
| C48.2 | Malignant neoplasm of peritoneum, unspecified | Can lead a claim | K | Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum |
| C48.8 | Malignant neoplasm of overlapping sites of retroperitoneum and peritoneumCMS: Malig neoplasm of ovrlp sites of retroperiton and peritoneum | Can lead a claim | K | Malignant Neoplasm of Pancreas, Peritoneum and Retroperitoneum |
Sources: CMS HH PPS Grouper Software v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.
The monthly home health regs digest
What CMS changed, what's due next, and what to do about it — one email a month, no fluff. Read the first issue